SHL GM Frank Isaksson to speak at the 2011 Injectable Drug Delivery Conference
pharmafile | January 25, 2011 | News story | Manufacturing and Production, Medical Communications | auto injector, autoinjector, frank isaksson, injectable drug delivery
With a steadily increasing number of biologics coming to market, the demand for auto injectors and similar devices continues to grow. The goal of events such as Injectable Drug Delivery (The World of Auto, Pen & Needle-free Injectors: Advances in Devices and Technology) is to bring experts from around the world together to share experiences and best practices related to drug delivery. A number of leading industry experts have been invited to speak and attendees from around the world will be at this specialized event.
This is SHL GM Frank Isaksson’s 6th time to speak at the Management Forum’s annual conference in the UK. Held on March 24th & 25th 2011 at Le Meridien Hotel, Piccadilly, London, participants at the event will be given the opportunity to listen to a diverse number of speakers from both Drug Delivery companies and also Pharmaceutical/Biotechnology companies.
Commenting on the event, Frank Isaksson stated, “I will illustrate examples of both the right and wrong approaches I have observed when working towards launching an auto-injector combination product. When looking at the right combination product to use for your company’s drug there are a vast number of topics to consider. Working at SHL, a leading producer of auto injectors & pen injectors, for 16 years now I have had the opportunity to be involved in a number of projects and understand potential pitfalls as well as best practices. I am confident that my talk will be helpful to those listening and I look forward to answering questions and having a stimulating discussion”.
For more information about this event and related speakers please go to: http://www.management-forum.co.uk/medical/eventid/1475
About SHL
SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 1,500 staff globally (1000 staff in Taiwan), with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia.
SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
Our organization consists of three distinct group companies:
SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies
SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use
SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products
For additional information visit www.shl-group.com or contact us at info@shl-group.com
SHL Media Contact
Steven R. Kaufman
Marketing Director
+886 932 111 460
pr@shl-group.com
Related Content
Novartis secures US rights to Adamis’ epinephrine auto injector
Novartis has penned an agreement with Adamis Pharmaceuticals to commercialise and distribute the latter’s epinephrine …
FDA unveils guidelines to help generic medical device versions reach the market
The scandal surrounding Mylan’s price-hiking of its flagship EpiPen epinephrine auto-injector was the news of …
SHL brings innovation to Pharmapack Europe 2017
As a forward-looking company with extensive knowledge and experience, SHL delivers solutions for today on …
